Beijing, China – 15 Sep 2026 – The Party Group of the National Medical Products Administration (NMPA) and the Discipline Inspection and Supervision Group of the State Administration for Market Regulation (SAMR) convened their second‑half 2026 regular meeting on comprehensive strict Party governance, holding a dedicated session on supporting the development of innovative drugs and medical devices. Lin Guoyao, head of the SAMR‑stationed supervision group and SAMR Party Group member, and Huang Guo, SAMR Party Group member and NMPA Party Group Secretary and Administrator, attended and addressed the meeting.
Meeting Snapshot
| Item | Detail |
|---|---|
| Date | 15 September 2026 |
| Convening Bodies | NMPA Party Group; Discipline Inspection and Supervision Group stationed at SAMR (CCDI/NSC) |
| Format | Regular half‑year consultation meeting on comprehensive strict Party governance |
| Core Agenda | Political oversight plus dedicated consultation on supporting innovative drugs and medical devices |
| Key Attendees | Lin Guoyao (SAMR supervision group head); Huang Guo (NMPA Party Group Secretary & Administrator); NMPA Party Group members Lei Ping, Yang Sheng, Wang Weidong; heads of relevant NMPA departments and directly affiliated units |
| Stated Results | Progress report on H1 2026 consultation tasks; deployment of supervisory recommendations for H2 |
Supervisory Assessment – Lin Guoyao
- Reform Track Record: The NMPA has deepened review and approval reform under the “Four Strictest” requirements — strictest standards, supervision, punishment, and accountability — driving year‑on‑year growth in approvals of innovative drugs and devices, described as an “acceleration” in promoting innovation, while acknowledging remaining shortcomings.
- Execution Discipline: Strengthen organizational leadership and reform‑advancement mechanisms, with enhanced inspection, tracking, and accountability to implement reform tasks in detail.
- Development–Safety Balance: Proactively empower innovative drug and device R&D while comprehensively upgrading drug safety regulatory capacity to detect and处置 risks early.
- “Three‑Medical” Coordination: More actively integrate into the coordinated development and governance of healthcare, medical insurance, and pharmaceuticals, align regulation with clinical needs, and guide local coordination of reform measures.
- Global Engagement: Deepen international regulatory cooperation and mutual recognition, assess industry trends precisely, and integrate further into global drug and device safety governance.
- Regulatory Science & Talent: Promote deep integration of regulatory science with industrial development and implement the guidance on strengthening drug regulation talent work in the new era.
NMPA Deployment – Huang Guo
- H1 Review: Reported progress on H1 2026 consultation tasks and the NMPA’s work supporting innovative development across drugs, medical devices, and cosmetics; deployed implementation of the supervision group’s recommendations.
- “Service + Review & Approval” Mechanism: Refine the new service‑oriented approval mechanism to encourage pharmaceutical R&D innovation, advance cell and gene therapy drug development and new‑method research, and support high‑level self‑reliance in medical devices.
- Lifecycle Regulation: Strengthen full‑lifecycle oversight — institutionalize drug safety risk consultation, intensify quality supervision of centrally procured (VBP) winning products, and enhance post‑market monitoring and evaluation of innovative products.
- Modernization & AI: Advance modernization of drug regulation, deepen the application of artificial intelligence in regulatory work, intensify regulatory science research, and participate deeply in global drug safety governance.
- Strict Governance: Compact political responsibility for Party administration, maintain a high‑pressure anti‑corruption posture, continue the “Qinglang Yaojian” (Clear and Bright Drug Regulation) special campaign, and improve constraints and supervision over the exercise of power.
Industry Impact & Outlook
- Approval Momentum: The leadership’s framing — rising innovative drug and device approval counts attributed to sustained review‑reform “acceleration” — signals continuity of the pro‑innovation approval posture into H2 2026 and beyond.
- Frontier Modalities: Explicit backing for cell and gene therapy development and device self‑reliance points to sustained policy support for advanced‑therapy sponsors and domestic device manufacturers.
- VBP Quality Scrutiny: Heightened supervision of centrally procured winning products raises the compliance bar for manufacturers holding volume‑based procurement awards — quality performance will be watched as closely as price.
- AI‑Enabled Regulation: Deepening AI application in regulatory work suggests evolving review workflows and data expectations for industry submissions.
- Governance Overlay: The coupling of Party‑governance discipline with regulatory policy underscores that reform execution and anti‑corruption compliance remain central to the NMPA’s operating model.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding NMPA regulatory reform priorities, supervision of innovative drugs and medical devices, and governance initiatives for the second half of 2026. Actual implementation may differ based on policy decisions, supervisory review outcomes, and evolving regulatory practice.-China Health Reform Pulse
Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260916083706136.html